Skip to main content
SMS Pharmaceuticals Ltd logo

SMS Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · SMSPHARMA ISIN · INE812G01025 LEI · 335800XXEADQCB7GJ514 BSE.NS Manufacturing
Open in API
Filings indexed 747 across all filing types
Latest filing 2020-09-10 Regulatory Filings
Country IN India
Listing BSE.NS SMSPHARMA

About SMS Pharmaceuticals Ltd

https://smspharma.com/

SMS Pharmaceuticals Ltd specializes in the development and large-scale manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The organization operates multiple manufacturing units and research centers, maintaining compliance with international regulatory standards including USFDA approvals. Its core product portfolio covers therapeutic areas such as anti-ulcerants, anti-migraine agents, anti-hypertensives, and anti-retrovirals. Beyond its proprietary product line, the company provides Contract Research and Manufacturing Services (CRAMS), offering expertise in process development, chemical synthesis, and analytical validation. The company focuses on delivering high-quality chemical solutions through integrated research and development capabilities, supporting global supply chains with a commitment to technical excellence and operational efficiency.

Recent filings

Filing Released Lang Actions
Book Closure
Regulatory Filings Classification · 100% confidence The document text is extremely short (64 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, no report content, no announcements, or any textual information to classify as a specific report type. Given the lack of content, the document cannot be classified as a report or announcement. According to the rules, such minimal or placeholder content defaults to Regulatory Filings (RNS) as a fallback category.
2020-09-10 English
Updates
Regulatory Filings
2020-09-08 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (64 characters) and contains no substantive content, financial data, or any indication of report type. It only includes a placeholder for an omitted picture and no other information. Given the lack of content, this cannot be classified as a full report or detailed filing. It fits best as a Regulatory Filing (RNS) which serves as a fallback category for miscellaneous or insufficient filings.
2020-09-07 English
Updates
Regulatory Filings
2020-09-07 English
Updates
Major Shareholding Notification Classification · 100% confidence The document is a detailed disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, along with references to SEBI (Prohibition of Insider Trading) Regulations, 2015. It includes specifics about share acquisitions by Potluri Laboratories Private Limited and an individual, Ramesh Babu Potluri, including shareholding percentages before and after acquisition, mode of acquisition, dates, and other regulatory details. The document is addressed to stock exchanges and corporate filing departments, indicating it is a formal regulatory disclosure about a substantial acquisition of shares and insider trading compliance. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is not an annual report, earnings release, or any other financial report type, nor is it a simple announcement or certification. It is a regulatory filing specifically about shareholding changes under SEBI regulations.
2020-08-18 English
Updates
Regulatory Filings
2020-08-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.